CD63 表达在实体瘤中的预后价值：文献的荟萃分析。
Prognostic Value of CD63 Expression in Solid Tumors: A Meta-analysis of the Literature.
机构信息
Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea.
Department of Pathology, Jeju National University School of Medicine, Jeju, Republic of Korea.
出版信息
In Vivo. 2020 Sep-Oct;34(5):2209-2215. doi: 10.21873/invivo.12031.
BACKGROUND
CD63 has been described as a key factor in extracellular vesicle production and endosomal cargo sorting, and there have been certain reports suggesting an association between CD63 expression and survival in patients with tumors including gastric, colon and lung cancer. However, the prognostic value of CD63 expression remains contradictory. Hence, we performed this meta-analysis to assess the prognostic value of CD63 expression in solid tumors.
MATERIALS AND METHODS
Eligible studies were collected by searching the PubMed, Embase and Cochrane libraries. The hazard ratio (HR) with 95% confidence interval (CI) were evaluated to reveal the association between CD63 expression and survival in solid tumors.
RESULTS
Five studies with a total of 1,454 patients were included. The HR evaluating CD63 expression on survival was 1.34 (95%CI=0.92-1.97, p=0.129). In subgroup analysis, the HRs of lung cancer and other tumors were 0.50 (95% CI=0.32-0.77, p=0.002) and 2.16 (95% CI=1.93-2.42, p<0.001) respectively. CD63 expression was significantly associated with poor disease-specific survival (HR=1.69, 95% CI=1.15-2.49, p=0.008), but not with disease-free survival and overall survival. Also, there was a significant association between CD63 expression with poor survival in the group of sample size more than 150 patients (HR=2.15, 95% CI=2.92-2.41, p<0.001), but not in the group of sample size with fewer than 150 patients.
CONCLUSION
This meta-analysis suggested that CD63 expression may be a potential prognostic marker in solid tumors.
背景
CD63 已被描述为细胞外囊泡产生和内体货物分拣的关键因素，有一些报告表明 CD63 表达与包括胃癌、结肠癌和肺癌在内的肿瘤患者的生存有关。然而，CD63 表达的预后价值仍然存在争议。因此，我们进行了这项荟萃分析，以评估 CD63 表达在实体瘤中的预后价值。
材料和方法
通过检索 PubMed、Embase 和 Cochrane 图书馆收集符合条件的研究。使用风险比（HR）及其 95%置信区间（CI）评估 CD63 表达与实体瘤生存之间的关系。
结果
纳入了五项共 1454 名患者的研究。评估 CD63 表达对生存的 HR 为 1.34（95%CI=0.92-1.97，p=0.129）。亚组分析显示，肺癌和其他肿瘤的 HR 分别为 0.50（95%CI=0.32-0.77，p=0.002）和 2.16（95%CI=1.93-2.42，p<0.001）。CD63 表达与疾病特异性生存率差显著相关（HR=1.69，95%CI=1.15-2.49，p=0.008），但与无病生存率和总生存率无关。此外，在样本量大于 150 例的组中，CD63 表达与较差的生存之间存在显著关联（HR=2.15，95%CI=2.92-2.41，p<0.001），但在样本量小于 150 例的组中则没有显著关联。
结论
这项荟萃分析表明，CD63 表达可能是实体瘤中潜在的预后标志物。
Zotero 插件